| Identification | Back Directory | [Name]
GW-6604 | [CAS]
452342-37-9 | [Synonyms]
GW-6604
GW6604;GW-6604;GW 6604.
2-phenyl-4-(5-pyridin-2-yl-1H-pyrazol-4-yl)pyridine
2-Phenyl-4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridine
Pyridine, 2-phenyl-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]- | [Molecular Formula]
C19H14N4 | [MDL Number]
MFCD20528050 | [MOL File]
452342-37-9.mol | [Molecular Weight]
298.34 |
| Chemical Properties | Back Directory | [Melting point ]
147 °C(Solv: dichloromethane (75-09-2); pentane (109-66-0)) | [Boiling point ]
505.2±50.0 °C(Predicted) | [density ]
1.226±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
8.80±0.50(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
GW-6604 is an ALK5 inhibitor with an IC50 value of 140 nM for inhibiting its autophosphorylation, and can be used in the study of liver fibrosis[1]. | [in vivo]
GW-6604(p.o., 25-80 mg/kg, twice a day, 3 weeks) dependently inhibits hepatic COL IA1 overexpression in an acute DMN model in SD rats, reducing its expression by 80%. Normal liver weight was maintained, liver fibrosis was effectively reduced and matrix degeneration was increased[1].
| [References]
[1] Anne-Charlotte de Gouville, et al. Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis. Br J Pharmacol. 2005 May;145(2):166-77. DOI:10.1038/sj.bjp.0706172 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|